• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Viable SARS-CoV-2 detected in the air of hospital rooms of COVID-19 patients with early infection

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2022 Nov 7;S1201-9712(22)00589-6.
doi: 10.1016/j.ijid.2022.11.003. Online ahead of print.
Viable SARS-CoV-2 detected in the air of hospital rooms of COVID-19 patients with early infection


Hiroki Kitagawa[SUP] 1 [/SUP], Toshihito Nomura[SUP] 2 [/SUP], Yuki Kaiki[SUP] 3 [/SUP], Masaki Kakimoto[SUP] 4 [/SUP], Tanuza Nazmul[SUP] 5 [/SUP], Keitaro Omori[SUP] 6 [/SUP], Norifumi Shigemoto[SUP] 7 [/SUP], Takemasa Sakaguchi[SUP] 5 [/SUP], Hiroki Ohge[SUP] 6 [/SUP]



Affiliations

Abstract

Objectives: This study assessed the concentration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the air of hospital rooms occupied by coronavirus disease (COVID-19) patients who had viable SARS-CoV-2 in nasopharyngeal samples in early infection.
Methods: Between July and October 2021, nasopharyngeal swabs were collected from 20 inpatients with early SARS-CoV-2 infection admitted to a tertiary hospital in Japan. Air samples were collected from their rooms, tested for SARS-CoV-2 RNA, and cultured to determine potential infectivity.
Results: The nasopharyngeal swab samples of 18 patients were positive for viable SARS-CoV-2 (median concentration: 4.0×10[SUP]5[/SUP] TCID50/mL). In the air samples, viral RNA (median concentration: 1.1×10[SUP]5[/SUP] copies/m[SUP]3[/SUP]) was detected in 12/18 (67%) patients and viable virus (median concentration: 8.9×10[SUP]2[/SUP] TCID50/m[SUP]3[/SUP]) was detected in 5/18 (28%) patients. The median time between illness onset and sampling was 3 days. The RNA concentration was significantly higher in samples wherein viable SARS-CoV-2 was detected than in samples in which viable virus was not detected (p = 0.027).
Conclusions: Viable SARS-CoV-2 can be detected in the air surrounding patients with early SARS-CoV-2 infection. Healthcare workers should pay attention to infection control when caring for patients with early SARS-CoV-2 infection.

Keywords: Delta SARS-CoV-2 variant; SARS-CoV-2; aerosol; air sampling; airborne transmission.
 
Back
Top Bottom